RAPT - חוב כולל להון rapt.com
The daily price chart for RAPT Therapeutics, Inc. (RAPT) reflects the 0.02 metric, driven by expectations surrounding dermatitis therapy and the potential for acquisition by industry behemoths. Meanwhile, market caution stems from a strategic development pivot following research pauses. The business relies on AI platforms that automate the creation of anti-tumor compounds, eliminating routine tasks for researchers.
%20-%20%D7%99%D7%97%D7%A1%20%D7%9B%D7%9C%D7%9C%20%D7%94%D7%97%D7%95%D7%91%D7%95%D7%AA%20%D7%9C%D7%9E%D7%A7%D7%95%D7%A8%D7%95%D7%AA%20%D7%A2%D7%A6%D7%9E%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_RAPT_-_RAPT-Therapeutics-Inc._-_All-Debt-to-Shareholders-Equity-Ratio "RAPT (RAPT Therapeutics, Inc.) היסטוריית חוב כולל להון מ-04.07.2022 עד 14.03.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. (RAPT) automates immuno-oncology design through robotic bio-screening and AI. The current leverage ratio (total debt to equity) reflects the proportion of borrowed funds relative to the company's own assets. This metric measures financial stability and the extent of the business's dependence on creditors. Analysis of this chart allows for an assessment of the balance between aggressive technological development and debt load. A low ratio confirms the funding autonomy of capital-intensive digital developments.